vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and SECURITY NATIONAL FINANCIAL CORP (SNFCA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $83.0M, roughly 1.0× SECURITY NATIONAL FINANCIAL CORP). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 4.7%). SECURITY NATIONAL FINANCIAL CORP produced more free cash flow last quarter ($43.8M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 1.1%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CNO Financial Group, Inc., formerly Conseco, Inc., is an American financial services holding company based in Carmel, Indiana. Its insurance subsidiaries provide life insurance, annuity and supplemental health insurance products to more than four million customers in the United States. These products are distributed through independent agents, career agents and direct to customers through television advertising and direct mail.
IOVA vs SNFCA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $83.0M |
| Net Profit | — | $13.5M |
| Gross Margin | 67.4% | 98.6% |
| Operating Margin | -84.7% | 20.9% |
| Net Margin | — | 16.3% |
| Revenue YoY | 17.7% | 4.7% |
| Net Profit YoY | — | 430.9% |
| EPS (diluted) | — | $0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $83.0M | ||
| Q3 25 | $67.5M | $89.3M | ||
| Q2 25 | $60.0M | $89.5M | ||
| Q1 25 | $49.3M | $82.7M | ||
| Q4 24 | $73.7M | $79.3M | ||
| Q3 24 | $58.6M | $88.3M | ||
| Q2 24 | $31.1M | $85.8M | ||
| Q1 24 | $715.0K | $81.2M |
| Q4 25 | — | $13.5M | ||
| Q3 25 | $-91.3M | $7.8M | ||
| Q2 25 | $-111.7M | $6.5M | ||
| Q1 25 | $-116.2M | $4.3M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | $-83.5M | $11.8M | ||
| Q2 24 | $-97.1M | $7.3M | ||
| Q1 24 | $-113.0M | $7.5M |
| Q4 25 | 67.4% | 98.6% | ||
| Q3 25 | 43.0% | 98.8% | ||
| Q2 25 | 5.5% | 98.7% | ||
| Q1 25 | -0.8% | 98.5% | ||
| Q4 24 | 68.7% | 98.5% | ||
| Q3 24 | 46.2% | 98.7% | ||
| Q2 24 | -0.8% | 98.6% | ||
| Q1 24 | — | 98.4% |
| Q4 25 | -84.7% | 20.9% | ||
| Q3 25 | -140.7% | 11.4% | ||
| Q2 25 | -189.8% | 9.3% | ||
| Q1 25 | -245.8% | 6.7% | ||
| Q4 24 | -117.5% | 4.0% | ||
| Q3 24 | -152.1% | 17.2% | ||
| Q2 24 | -327.6% | 10.9% | ||
| Q1 24 | -16464.6% | 11.8% |
| Q4 25 | — | 16.3% | ||
| Q3 25 | -135.3% | 8.7% | ||
| Q2 25 | -186.2% | 7.3% | ||
| Q1 25 | -235.5% | 5.2% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | -142.7% | 13.4% | ||
| Q2 24 | -312.2% | 8.5% | ||
| Q1 24 | -15800.8% | 9.2% |
| Q4 25 | — | $0.52 | ||
| Q3 25 | — | $0.31 | ||
| Q2 25 | $-0.33 | $0.25 | ||
| Q1 25 | $-0.36 | $0.18 | ||
| Q4 24 | $-0.24 | $0.09 | ||
| Q3 24 | $-0.28 | $0.47 | ||
| Q2 24 | $-0.34 | $0.29 | ||
| Q1 24 | $-0.42 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $102.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $410.4M |
| Total Assets | $913.2M | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $102.3M | ||
| Q3 25 | $300.8M | $100.4M | ||
| Q2 25 | $301.2M | $79.3M | ||
| Q1 25 | $359.7M | $132.9M | ||
| Q4 24 | $323.8M | $140.5M | ||
| Q3 24 | $397.5M | $170.7M | ||
| Q2 24 | $412.5M | $143.6M | ||
| Q1 24 | $356.2M | $150.9M |
| Q4 25 | $698.6M | $410.4M | ||
| Q3 25 | $702.3M | $365.4M | ||
| Q2 25 | $698.5M | $354.8M | ||
| Q1 25 | $767.9M | $346.5M | ||
| Q4 24 | $710.4M | $381.9M | ||
| Q3 24 | $773.5M | $346.3M | ||
| Q2 24 | $768.5M | $325.8M | ||
| Q1 24 | $680.0M | $320.1M |
| Q4 25 | $913.2M | $1.6B | ||
| Q3 25 | $904.9M | $1.6B | ||
| Q2 25 | $907.4M | $1.5B | ||
| Q1 25 | $966.7M | $1.5B | ||
| Q4 24 | $910.4M | $1.5B | ||
| Q3 24 | $991.1M | $1.5B | ||
| Q2 24 | $964.3M | $1.5B | ||
| Q1 24 | $869.8M | $1.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $45.5M |
| Free Cash FlowOCF − Capex | $-61.9M | $43.8M |
| FCF MarginFCF / Revenue | -71.3% | 52.8% |
| Capex IntensityCapex / Revenue | 10.7% | 2.0% |
| Cash ConversionOCF / Net Profit | — | 3.38× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $69.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $45.5M | ||
| Q3 25 | $-78.7M | $25.6M | ||
| Q2 25 | $-67.4M | $-7.7M | ||
| Q1 25 | $-103.7M | $9.6M | ||
| Q4 24 | $-73.3M | $57.3M | ||
| Q3 24 | $-59.0M | $26.8M | ||
| Q2 24 | $-98.4M | $-17.0M | ||
| Q1 24 | $-122.3M | $25.1M |
| Q4 25 | $-61.9M | $43.8M | ||
| Q3 25 | $-89.5M | $24.9M | ||
| Q2 25 | $-74.9M | $-8.1M | ||
| Q1 25 | $-109.9M | $9.1M | ||
| Q4 24 | $-77.5M | $54.8M | ||
| Q3 24 | $-61.3M | $26.6M | ||
| Q2 24 | $-98.9M | $-17.1M | ||
| Q1 24 | $-126.5M | $24.8M |
| Q4 25 | -71.3% | 52.8% | ||
| Q3 25 | -132.7% | 27.9% | ||
| Q2 25 | -124.9% | -9.1% | ||
| Q1 25 | -222.8% | 11.1% | ||
| Q4 24 | -105.1% | 69.2% | ||
| Q3 24 | -104.6% | 30.2% | ||
| Q2 24 | -317.9% | -20.0% | ||
| Q1 24 | -17685.3% | 30.6% |
| Q4 25 | 10.7% | 2.0% | ||
| Q3 25 | 16.1% | 0.8% | ||
| Q2 25 | 12.4% | 0.5% | ||
| Q1 25 | 12.6% | 0.5% | ||
| Q4 24 | 5.7% | 3.1% | ||
| Q3 24 | 3.9% | 0.2% | ||
| Q2 24 | 1.4% | 0.2% | ||
| Q1 24 | 583.4% | 0.3% |
| Q4 25 | — | 3.38× | ||
| Q3 25 | — | 3.28× | ||
| Q2 25 | — | -1.18× | ||
| Q1 25 | — | 2.21× | ||
| Q4 24 | — | 22.55× | ||
| Q3 24 | — | 2.26× | ||
| Q2 24 | — | -2.33× | ||
| Q1 24 | — | 3.36× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
SNFCA
| Life Insurance | $29.9M | 36% |
| Mortgage | $24.8M | 30% |
| Other | $21.3M | 26% |
| Timing Of Revenue Recognition Goods Transferred At A Point In Time | $4.6M | 6% |
| Timing Of Revenue Recognition Services Transferred At A Point In Time | $2.4M | 3% |
